Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2017 Dec 1;135(12):1426-1429.
doi: 10.1001/jamaophthalmol.2017.4600.

Risk of Extraocular Extension in Eyes With Retinoblastoma Receiving Intravitreous Chemotherapy

Jasmine H Francis  1   2 , David H Abramson  1   2 , Xunda Ji  3 , Carol L Shields  4 , Luiz F Teixeira  5   6 , Amy C Schefler  7 , Nathalie Cassoux  8 , Doris Hadjistilianou  9 , Jesse L Berry  10 , Shahar Frenkel  11 , Francis L Munier  12
Affiliations
Multicenter Study

Risk of Extraocular Extension in Eyes With Retinoblastoma Receiving Intravitreous Chemotherapy

Jasmine H Francis et al. JAMA Ophthalmol. .

Abstract

Importance: The risk of extraocular extension from injecting chemotherapy into eyes with retinoblastoma is minimally understood; however, understanding this risk is important because of the increasing use of intravitreous chemotherapy.

Objective: To evaluate the risk of extraocular extension in eyes with retinoblastoma that have received intravitreous chemotherapy injections.

Design, setting, and participants: This retrospective cohort study was performed in 655 patients at 10 retinoblastoma centers in North and South American, European, Israeli, and Chinese centers. Physicians at the retinoblastoma centers administered more than 120 intravitreous chemotherapy injections in eyes with retinoblastoma from February 1, 1999, through February 28, 2017.

Main outcomes and measures: Risk of extraocular extension with secondary observational variables, including injection and precautionary techniques.

Results: A total of 3553 intravitreous chemotherapy injections (3201 melphalan hydrochloride, 335 topotecan hydrochloride, and 17 methotrexate sodium) were administered to 704 eyes in 655 patients with retinoblastoma (mean [SD] age of patients at the time of the initial injections, 31.6 [11.6] months; 348 male [53.1%]). There were no extraocular tumor events related to prior intravitreous injections. This finding resulted in a calculated proportion of zero extraocular events per eye. According to the rule of 3, the risk is no greater than 0.08% injections. All 10 centers included in this study used at least 2 presumed precautionary injection methods (lowering of intraocular pressure, cryotherapy, ocular surface irrigation, ultrasonic biomicroscopy surveillance of the injection site, and subconjunctival chemotherapy deposition).

Conclusions and relevance: With use of at least 2 presumed precautionary safety methods, no extraocular extension of tumor events occurred. According to the rule of 3, this finding suggests that the risk is no greater than 0.08% injections.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

References

    1. Karcioglu ZA. Fine needle aspiration biopsy (FNAB) for retinoblastoma. Retina. 2002;22(6):707-710. - PubMed
    1. Honavar SG, Shields CL, Shields JA, Demirci H, Naduvilath TJ. Intraocular surgery after treatment of retinoblastoma. Arch Ophthalmol. 2001;119(11):1613-1621. - PubMed
    1. Smith SJ, Smith BD. Evaluating the risk of extraocular tumour spread following intravitreal injection therapy for retinoblastoma: a systematic review. Br J Ophthalmol. 2013;97(10):1231-1236. doi: 10.1136/bjophthalmol-2013-303188 - DOI - PubMed
    1. Hanley JA, Lippman-Hand A. If nothing goes wrong, is everything all right? interpreting zero numerators. JAMA. 1983;249(13):1743-1745. - PubMed
    1. Ericson LA, Rosengren BH. Present therapeutic resources in retinoblastoma. Acta Ophthalmol (Copenh). 1961;39:569-576. - PubMed

Publication types